ABOUT US
Who We Are?
Founded in 1994, Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction and pain management. Rusan’s manufacturing company for active pharmaceutical ingredients (API) and finished pharmaceutical formulations, live up to some of the highest standards of good manufacturing practices (GMP) and are approved by Health Africa.
Rusan Pharma Africa Inc. (RPCI) is the African subsidiary of Rusan Pharma Ltd. (India), a generic pharmaceutical company located in Montreal, Québec. With a strong product development pipeline and strategic partnerships, we pride ourselves in delivering high quality and affordable generic pharmaceutical medicines to the African market. Through product differentiation, best-in-class supply and excellent service, we strive to help families across Africa live longer, healthier and happier lives.
Our Mission
Rusan firmly believes that access to quality healthcare is a right, not a privilege. We will endeavour to ensure the availability of world class, innovative, quality medicines at affordable prices, across the globe and are committed to work towards a healthier & happier world.
Our Vision
To bring forward innovative, highly quality novel and generic medications at affordable prices for our consumers.
OUR LEADERS
Dr. Kunal Saxena
Managing Director, Rusan PharmaA technocrat with wide exposure to process development, synthetic chemistry & commercialization of bulk drugs. A practicing technocrat with vast experience in research & development. Specialised in computer-aided drug design and new chemical entity synthesis including chiral synthesis. Dr. Kunal Saxena has done his Ph.D. in Pharmacology from the University of Bristol (UK), M.Sc. in Chemistry from Moscow State University (Moscow, Russia) and B.Sc. in Biochemistry from the University of Notre Dame (USA). Has done basic research in the area of opioid receptors and developed several novel non-opioid compounds that help reduce side effects and tolerance to opioid analgesics.
Dr. Aakarsh Saxena
Director, Rusan PharmaDr. Aakarsh Saxena, based in Mumbai, is currently a Director at Rusan Pharma Ltd, bringing experience from previous roles at The University of Texas at Austin, The University of Edinburgh, William & Mary and Rusan Pharma Ltd. Dr. Aakarsh Saxena holds a 2008 - 2013 Doctor of Philosophy (Ph.D.) from The University of Edinburgh. With a robust skill set that includes Chemistry, Organic Chemistry, Catalysis, Asymmetric Catalysis, NMR Spectroscopy and more, Dr. Aakarsh Saxena contributes valuable insights to the industry.
Dr. Navin Saxena
Chairman, Rusan PharmaPh.D. in Synthetic Organic Chemistry from Moscow Friendship University. Dr. Navin Saxena started his career in 1981 as a Research Officer and within a short span of 10 years reached the level of Vice President and Head of Research. Dr. Navin Saxena is not only the youngest recipient of this award, but also the first Indian to receive this accolade. On 29th July 1997, Dr. Saxena in the capacity of being the Chairman of Rusan Pharma Ltd. was honoured with "THE INTERNATIONAL EXECLLENCE AWARD" by the Council for Small and Medium Exporters for excellence in exporting medicines. Dr. Saxena was also awarded the prestigious "UDYOG RATTAN AWARD" by the Institute for Economic Studies for his contribution in the field of industrial development in India.
API
API Active Pharmaceutical Ingredient (API)
| Sr. No. | API Name | GRADE | Approval status CEP/ DMF | CAS No. |
|---|---|---|---|---|
| 1 | Buprenorphine | EP/BP/USPSP | Rl-CEP 2015-387 - Rev 00 | 52485-79-7 |
| 2 | Buprenorphine HCl | Ph. Eur. / USP | R1-CEP 2017-228 - Rev 00 | 53152-21-9 |
| 3 | Fentanyl | Ph. Eur. / USP | Rl-CEP 2016-018 - Rev 00 | 437-38-7 |
| 4 | Fentanyl Citrate | Ph. Eur. / USP | R1-CEP 2016-023 - Rev 00 | 990-73-8 |
| 5 | Naltrexone HCl | Ph. Eur. / USP | Rl-CEP 2016-053 - Rev 00 | 51481-60-8 |
| 6 | Methadone HCl | Ph. Eur. / USP | R0-CEP 2017-277 - Rev 02 | 1095-90-5 |
| 7 | Bisoprolol Fumarate | Ph. Eur. / USP | R0-CEP 2020-095- Rev 00 | 104344-23-2 |
| 8 | Apomorphine HCl | Ph. Eur. / USP | CEP 2021-135 - Rev 00 | 41372-20-7 |
| 9 | Naloxone HCl | Ph. Eur. / USP | CEP 2022-086 - Rev 00 | 51481-60-8 |
| 10 | Diazepam | Ph. Eur. | CEP 2024-260 | 439-14-5 |
| 11 | Eflornithine HCl | Non-pharmacopeial | EMA approved EU/ASMF/00137 Active US DMF (№ 031780) |
96020-91-6 |
| 12 | Nalmefene HCl | Non-pharmacopeial | Active US DMF (№ 034367) | 1228646-72-7 |
| 13 | Nalbuphine HCl | Non-pharmacopeial | DMF Available | 23277-43-2 |
| 14 | Promedol HCl | Non-pharmacopeial | DMF Available | 64-39-1 |
| 15 | n-Butyl Cyanoacrylate | Non-pharmacopeial | DMF Available | 6606-65-1 |
| 16 | Sodium Oxybate | Non-pharmacopeial | DMF Available | 502-85-2 |
| 17 | Clonazepam | Non-pharmacopeial | DMF Available | 1622-61-3 |
| 18 | Oxycodone HCl | Non-pharmacopeial | DMF Available | 124-90-3 |
API Active Pharmaceutical Ingredient (API)
| Sr. No. | API Name | GRADE | CAS No. |
|---|---|---|---|
| 1 | Carbamazepine | Ph. Eur. | 298-46-4 |
| 2 | Remifentanil HCl | Ph. Eur. | 132539-07-2 |
| 3 | Sufentanyl | Ph. Eur. | 56030-54-7 |
| 4 | Sufentanyl Citrate | Ph. Eur. | 60561-17-3 |
| 5 | Alfentanil HCl | Ph. Eur. | 69049-06-5 |
| 6 | Midazolam | Ph. Eur. | 59467-70-8 |
| 7 | Dihydrocodeine Hydrogen Tartrate | Ph. Eur. | 5965-13-9 |
| 8 | Hydromorphone HCl | Ph. Eur. | 71-68-1 |
| 9 | Hydrocodone Hydrogen Tartrate | Ph. Eur. | 125-29-1 |
| 10 | Oxymorphone HCl | USP | 357-07-3 |
| 11 | Tramadol HCl | Ph. Eur. | 36282-47-0 |
| 12 | Pregabalin | Ph. Eur. | 148553-50-8 |
| 13 | Methyl Naltrexone Bromide | Ph. Eur. | 916055-92-0 |
Finished Formulation
All Products
| Sr no | Generic Name | Strength | Brand Name | Registration number | Fill Volume / Loading (if applicable) |
Pack Type | Pack Size |
|---|---|---|---|---|---|---|---|
| 1 | Caffeine, Codeine Phosphate, Meprobamate, Paracetamol Tablets | 32 mg + 8 mg + 150 mg + 320 mg | DYNAPAYNE TABLETS | Y/2.8/237 | -NA- | 1 HDPE bottle 5 Blisters of 20 Tablets /Blister in inner carton 2 Blisters of 20 Tablets /Blister in inner carton |
1000 100 40 |
| 2 | Paracetamol Tablets | 500 mg | DYNADOL TABLETS | 27/2.7/0352 | -NA- | 1 PRP Pack 1 Blister of 20 Tablets/Blister in inner carton 1 HDPE bottle with LDPE Security cap. |
20 20 100 |
| 3 | Sulphamethoxazole and Trimethoprim Tablets | 400 mg + 80 mg | TROXAZOLE TABLET | K/20.2/158 | -NA- | 1 PRP Pack 1 PRP Pack |
28 56 |
| 4 | Enalapril Maleate Tablets | 5 mg | Enalapril 5 Arya | 37/7.1.3/0327 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 5 | Enalapril Maleate Tablets | 10 mg | Enalapril 10 Arya | 37/7.1.3/0328 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 6 | Enalapril Maleate Tablets | 20 mg | Enalapril 20 Arya | 37/7.1.3/0329 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 7 | Olanzapine Tablets | 2.5 mg | Olandus 2.5 | 44/2.6.5/0977 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 8 | Olanzapine Tablets | 5 mg | Olandus 5 | 44/2.6.5/0978 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 9 | Olanzapine Tablets | 10 mg | Olandus 10 | 44/2.6.5/0979 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 10 | Nalbuphine Injection | 10 mg/ml (1 ml Ampoule) | Nalbain Injection 10mg/ml | 51/2.9/0360 | 1 ml | 1 tray of 10 Ampoules in one Inner Carton | 10 |
| 11 | Nalbuphine Injection | 20 mg/ml (1 ml Ampoule) | Nalbain Injection 20mg/ml | 51/2.9/0362 | 1 ml | 1 tray of 5 Ampoules in one Inner Carton | 5 |
| 12 | Ciprofloxacin Tablets | 250 mg | BIOFLOXX 250 | A40/20.1.1/0371 | -NA- | 1 HDPE bottle 1 HDPE bottle 1 Blisters of 10 Tablets /Blister in inner carton |
50 100 10 |
| 13 | Ciprofloxacin Tablets | 500 mg | BIOFLOXX 500 | A40/20.1.1/0372 | -NA- | 1 HDPE bottle 1 HDPE bottle 1 Blisters of 10 Tablets /Blister in inner carton |
50 100 10 |
| 14 | Ciprofloxacin Tablets | 750 mg | BIOFLOXX 750 | A40/20.1.1/0373 | -NA- | 1 HDPE bottle 1 HDPE bottle |
50 100 |
| 15 | Oxazepam Tablets | 15 mg | ZIMTEC 15 | Q/2.6/292 | -NA- | 10 Blisters of 10 Tablets /Blister in inner carton | 100 |
| 16 | Oxazepam Tablets | 30 mg | ZIMTEC 30 | Q/2.6/293 | -NA- | 10 Blisters of 10 Tablets /Blister in inner carton | 100 |
| 17 | Atenolol Tablets | 50 mg | Atenolol 50 Arya | 30/5.2/0026 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 18 | Atenolol Tablets | 100 mg | Atenolol 100 Arya | 30/5.2/0035 | -NA- | 2 Blisters of 14 Tablets /Blister in inner carton | 28 |
| 19 | Doxycycline Tablets | 100 mg | DOXYMED | 32/20.1.1/0117 | -NA- | 1 PRP Pack 1 HDPE bottle with LDPE Security cap. |
10 100 |
| 20 | Tranexamic Acid Injection | 100 mg/ml | Arytrans IV (5 ml Ampoule) | 48/8.1/0053 | 5 ml | 1 tray of 5 Ampoules in one Inner Carton | 5 |
| 21 | Minocycline Capsules | 50 mg | MINOCYCLINE 50 mg ARYA | 31/20.1.1/0130 | -NA- | 1 HDPE Bottle | 60 100 120 500 1000 |
| 22 | Minocycline Capsules | 100 mg | MINOCYCLINE 100 mg ARYA | 31/20.1.1/0131 | -NA- | 1 HDPE Bottle | 100 250 500 1000 |
| 23 | Cimetidine Tablets | 200 mg | CIMETIDINE 200 ARYA | 30/11.4.3/0046 | -NA- | 1 HDPE Bottle | 100 |
| 24 | Cimetidine Tablets | 400 mg | CIMETIDINE 400 ARYA | 30/11.4.3/0047 | -NA- | 1 HDPE Bottle | 100 |
| 25 | Paracetamol Syrup | 120 mg/5 ml (100 ml bottle) | DYNADOL SYRUP | 27/2.7/0353 | 100 ml | 1 Glass bottle in one inner carton | 1 |
| 26 | Diphenhydramine Hydrochloride, Ammonium chloride and Sodium Citrate Syrup | 12.50 mg + 125 mg + 50 mg / 5ml | FAMTUSS | G983 (Act 101/1965) | 50 ml 100 ml 200 ml 2.5 Liter |
1 PVC round Amber bottle(50 ml) with white
plastic snap on cap (28mm) 1 PVC round Amber bottle(100 ml) with white LDPE snap on cap (24mm) 1 PVC round Amber bottle(200 ml) with white LDPE snap on cap (31mm) 1 Amber HDPE Polycan(2500 ml) with white snap on cap (38mm) |
1 |
| 27 | Paracetamol Solution for Influsion | 10 mg/ml (100 ml Vial) | Dynadol IV | 52/2.7/0444 | 100 ml | Type 1 Glass vial (100 ml) in one inner carton
Translucent white LDPE Plastic bottle (Euro Head) 100ml in one inner carton Translucent white LDPE Plastic (Nipple head Bottle) 100ml in one inner carton |
1 |
| 28 | Levofloxacin Solution for Infusion | 500 mg/ml (100 ml Vial) | ALEFNIC 500 IV | 52/20.1.1/0278 | 100 ml | 1 Plastic bottle in one inner carton | 1 |
| 29 | Captopril Tablets | 25 mg | CAPTOPRIL 25 mg BIOTECH | 32/7.1/0006 | -NA- | 1 HDPE Bottle | 60 100 500 1000 |
| 30 | Captopril Tablets | 50 mg | CAPTOPRIL 50 mg BIOTECH | 32/7.1/0007 | -NA- | 1 HDPE Bottle | 60 100 500 1000 |
| 31 | Flunitrazepam Tablets | 1 mg | FLUNITRAZEPAM 1 BIOTECH | 35/2.2/0160 | -NA- | 3 Blisters of 10 Tablets /Blister in inner carton | 30 |
| 32 | Nifedipine Extended release Tablets | 30 mg | Nifedipine 30 XL Arya | 50/7.1/0502 | -NA- | 3 Blisters of 10 Tablets /Blister in inner carton | 30 |
| 33 | Nifedipine Extended release Tablets | 60 mg | Nifedipine 60 XL Arya | 50/7.1/0503 | -NA- | 3 Blisters of 10 Tablets /Blister in inner carton | 30 |
| 34 | Oxytetracycline Capsules | 250 mg | DYNOXYTET | X/20.1.1/319 | -NA- | 1 Securitainer 1 Securitainer 1 HDPE Bottle 1 PVC Bottle 1 PVC Bottle |
20 100 500 500 1000 |
| 35 | Dothiepin Hydrochloride Capsules | 25 mg | DOSULEPIN 25 BIOTECH | Z/1.2/162 | -NA- | Amber Glass Container securitainer sealed aluminium bags Blister Amber Glass Container securitainer sealed aluminium bags Blister |
90 90 90 90 100 100 100 100 |
| 36 | Dothiepin Hydrochloride Tablets | 75 mg | DOSULEPIN 75 BIOTECH | Z/1.2/163 | -NA- | Amber Glass Container securitainer sealed aluminium bags Blister Amber Glass Container securitainer sealed aluminium bags Blister Amber Glass Container securitainer blister |
28 28 28 28 30 30 30 30 500 500 500 |
| 37 | Cefaclor Tablets | 250 mg | CEFACLOR 250 BIOTECH | 31/20.1.1/0102 | -NA- | 1 white Plastic Bottle | 100 500 |
| 38 | Cefaclor Tablets | 500 mg | CEFACLOR 500 BIOTECH | 31/20.1.1/0103 | -NA- | 1 white Plastic Bottle | 100 250 500 |
| 39 | Erythromycin Capsules | 250 mg | Erythromycin 250 Biotech | L/20.1.1/92 | -NA- | 1 Plastic Bottle | 20 100 200 500 |
| 40 | Erythromycin Powder for Suspension | 125 mg / 5ml (100 ml) | Spectrasone S 125 | L/20.1.1/93 | 100 ml | 150ml round Amber Glass Bottle with PE cap in one inner carton | 1 |
| 41 | Flurbiprofen Tablets | 50 mg | ARYFLAM 50 mg | 32/3.1/0008 | -NA- | 1 HDPE bottle 1 HDPE bottle 1 HDPE bottle 10 Blisters of 10 Tablets /Blister in inner carton |
100 500 1000 100 |
| 42 | Flurbiprofen Tablets | 100 mg | ARYFLAM 100 mg | 32/3.1/0009 | -NA- | 1 HDPE bottle 1 HDPE bottle 1 HDPE bottle 10 Blisters of 10 Tablets /Blister in inner carton |
100 500 1000 100 |
| 43 | Amylmetacresol and 2,4-Dichlorobenzyl Alcohol Lozenges (Blackcurrant) | 0,6 mg 1,2 mg | Zeptaloz Blackcurrant | 57/16.4/0679.678 | -NA- | 1 Blister of 8 lozenges packed in an inner
carton 2 Blisters of 12 lozenges/blister packed in an inner carton |
8 24 |
| 44 | Amylmetacresol and 2,4- Dichlorobenzyl Alcohol Lozenges (Honey Lemon) |
0,6 mg 1,2 mg | Zeptaloz Honey Lemon | 57/16.4/0681.680 | -NA- | 1 Blister of 8 lozenges packed in an inner
carton 2 Blisters of 12 lozenges/blister packed in an inner carton |
8 24 |
| 45 | Amylmetacresol and 2,4- Dichlorobenzyl Alcohol Lozenges (Lemon) |
0,6 mg 1,2 mg | Zeptaloz Lemon | 57/16.4/0683.682 | -NA- | 1 Blister of 8 lozenges packed in an inner
carton 2 Blisters of 12 lozenges/blister packed in an inner carton |
8 24 |
| 46 | Amylmetacresol and 2,4- Dichlorobenzyl Alcohol Lozenges (Orange) |
0,6 mg 1,2 mg | Zeptaloz Orange | 57/16.4/0685.684 | -NA- | 1 Blister of 8 lozenges packed in an inner carton | 8 |
| 47 | Amylmetacresol and 2,4- Dichlorobenzyl Alcohol Lozenges (Orange) |
0,6 mg 1,2 mg | Zeptaloz Orange | 57/16.4/0685.684 | -NA- | 2 Blisters of 12 lozenges/blister packed in an inner carton | 24 |
Pain Management
| Product Description | Strength | Fill Size | Format | Pack Size | Rusan Code | DIN | Product Monograph | Know More |
|---|---|---|---|---|---|---|---|---|
| RPC - Nalbuphine Injection | 10 mg/ml | 1 ml | Ampoule | 10 | - | - |
|
|
| RPC - Nalbuphine Injection | 20 mg/ml | 1 ml | Ampoule | 5 | - | - |
|
Drug Dependence
| Product Description | Strength | Fill Size | Format | Pack Size | Rusan Code | DIN | Product Monograph | Know More |
|---|---|---|---|---|---|---|---|---|
| RPC – Methadone Hydrochloride Oral Concentrate (Cherry Flavoured Solution) | 10 mg/ml | 1000 ml | Syrup | 1 HDPE Bottle | - |
|
||
| RPC - Methadone Hydrochloride Oral Concentrate (Dye-Free, Sugar-Free, Unflavored Solution) | 10 mg/ml | 1000 ml | Syrup | 1 HDPE Bottle | - |
|
||
| RPC – Buprenorphine/ Naloxone Sublingual Tablet | 2/0.5 mg | N/A | Tablet | Strip of 30 Tablets |
|
|||
| RPC – Buprenorphine/ Naloxone Sublingual Tablet | 8/2 mg | N/A | Tablet | Strip of 30 Tablets | - | - |
|
Alcohol Dependence
| Product Description | Strength | Fill Size | Format | Pack Size | Rusan Code | DIN | Product Monograph | Know More |
|---|---|---|---|---|---|---|---|---|
| RPC – Naltrexone Tablet | 50 mg | N/A | Tablet | Strip of 30 Tablets | - | - |
|
Tobacco Dependence
| Generic Name | Strength | Formulation | Remarks |
|---|---|---|---|
| Nicotine Transdermal Patch | 21 mg / 24 hrs | Patch | Developed |
| Nicotine Transdermal Patch | 14 mg / 24 hrs | Patch | Developed |
| Nicotine Transdermal Patch | 7 mg / 24 hrs | Patch | Developed |
Over The Counter (OTC)
| Generic Name | Strength | Formulation | Remarks |
|---|---|---|---|
| Psyllium Husk Sachets | 3.5 g | Sachets | Registered |
Our Facilities
| Dosages Form |
|---|
|
Tablets |
|
Capsule |
|
Powder in Sachet |
|
Lyo Injectable (Vial / Bulk Powder) |
|
Small Volume Parenteral - Vial |
|
Small Volume Parenteral (Injectable) - Ampoule |
|
Cream & Ointment |
|
Beta-Lactam Capsule |
|
Beta-Lactam Dry Syrup |
Target Approval
| Dosages Form |
|---|
|
Tablet |
|
Capsule |
|
Oral Liquid - Solution / Suspension (30 ml to 1000 ml) |
|
Transdermal Patch |
|
Small Volume Parenteral (Injectable) - Vial |
|
Small Volume Parenteral (Injectable) - Ampoule |
|
Small Volume Parenteral (Injectable) - Prefilled Syringe |
Target Approval
R&D
Navin Saxena Research & Technology Pvt. Ltd. (NSRT)
NSRT, an affiliate of Rusan pharma, is a state-of-the-art research centre in the Kandla Special Economic Zone (KASEZ; Gujarat, India). With a rich experience of more than 25 years, in pharmaceutical development & manufacturing, NSRT is capable of undertaking cutting-edge research. Our research team comprises of versatile and specialized pool of scientists in the field of computer aided drug design, development and manufacturing of API and novel drug delivery systems.
NSRT is capable of undertaking R&D projects for custom API synthesis and development of finished formulations and in partnership with Rusan Pharma, undertake commercial production for the African market.
Quantys Clinical Pvt Ltd. (QCPL)
QCPL is a 104 bed clinical research organization (CRO) with five independent clinics with collapsible partitions, enabling QCPL to conduct large, mixed population and multiple studies at the same time. QCPL's trained & dedicated staff brings in considerable experience in conducting Pharmacokinetic (PK) and Clinical trial studies for various finished formulations.
QCPL's partnerships with Investigators, Institution, NGO’s, Hospitals and Clinics, enable it to recruit not just healthy volunteers but ‘Special Volunteer Groups’ to cater to the specific study requirements.
QCPL can provide PK and clinical trial study services to African Pharmaceutical companies looking to conduct such studies.
Product Pipeline
Innovation is the cornerstone of Rusan’s vision & mission. Our rich development portfolio focuses in the area of addiction treatment, pain management and Parkinson’s. To partner with Rusan on some of our novel & generic transdermal patch products connect with us: formulation.enquiry@rusanpharma.com
| Indication | Program / Regulatory Pathway | Preclinical | Phase-I | Phase-II | Phase-III | Approval |
|---|---|---|---|---|---|---|
| Alcohol Use Disorder | Antagonist Prodrug Sustained Release Injection (Monthly) |
|
||||
| Opioid Use Disorder | Partial Agonist Weekly & Monthly Sustained Release Injection |
|
||||
| Pain Management | Partial Agonist Monthly Sustained Release Injection |
|
||||
Generic Transdermal Patches & Oral Film
For exploring in-licensing opportunities for our transdermal patch portfolio for the African market, please Email us on: formulation.enquiry@rusanpharma.com
| Generic Name | Remarks |
|---|---|
| Nicotine Patch | Under Development |
| Nicotine Oral Flim | Under Development |
| Buprenorphine + Naloxone Sublingual Flim | Under Development |
| Buprenorphine Patch | Under Development |
| Fentanyl Patcht | Under Development |
| Rivastigmine Patch | Under Development |
| Rotigitine Patch | Under Development |
| Lidocaine Patch | Under Development |
CAREERS
"Great Products are the brainchild and hard work of great people. Join a young, dynamic, fast-growing and inclusive company where you have the opportunity to aim high, fulfil your potential, and achieve great things!"
Contact Us: career@rusanpharma.com
ADR REPORTING
Adr Reporting
Please provide details of the Event(s) that
occurred and Product(s) used, as descriptor of the
Person who experienced the event and contact details of
Reporter.
If you have a medical emergency, please contact your
doctor or other health care provider, or emergency services.
Please note that Rusan Pharma Africa Inc. is unable to
provide medical advice.
CONTACT US
Contact Us
Contract Manufacturing: formulation.enquiry@rusanpharma.com
In-Licensing Products: formulation.enquiry@rusanpharma.com
Product related Adverse Events: pv@rusanpharma.com
Careers: career@rusanpharma.com
Sales: sales@aryapharma.co.za
Our Office
Rusan Pharma Africa Inc (RPCI)
PHARMA HQ CORNER BARBARA AND NORTH REEF ROAD
ELANDSFONTEIN, HENVILLE, GERMISTON, Town/City: JOHANNESBURG
Province : GAUTENG; Postal Code: 1601
Reception: +27 100 600 740
Sales: +27 100 600 743; +27 100 600 742
Finance:+27 100 600 741
Responsible Pharmacist: +27 100 600 745
Copyright © Rusan Pharma Africa Inc. Designed by: WEBbrella Infotech.